Amyotrophic lateral sclerosis--the tools of the trait.
The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS-specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate-filament disorganization or axonal-transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem-cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.
Lederer
Carsten W
CW
Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Santama
Niovi
N
D000690:Amyotrophic Lateral Sclerosis / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D001709:Biotechnology / Q000379:methods*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009419:Nerve Tissue Proteins / Q000378:metabolism*
D015415:Biomarkers; D009419:Nerve Tissue Proteins